Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer

MLA

Hee Dong Han, et al. Endoglin (CD105) Contributes to Platinum Resistance and Is a Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer. Nov. 2012. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4549fad5ffada486bf269e6c16dc29b4&authtype=sso&custid=ns315887.

APA

Hee Dong Han, Monjri Shah, Anil K. Sood, Adam D. Steg, Michael G. Conner, Zachary C. Dobbin, Ashwini A. Katre, Eddy S. Yang, Angela Ziebarth, Charles N. Landen, Somaira Nowsheen, & Gabriel Lopez-Berestein. (2012). Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Chicago

Hee Dong Han, Monjri Shah, Anil K. Sood, Adam D. Steg, Michael G. Conner, Zachary C. Dobbin, Ashwini A. Katre, et al. 2012. “Endoglin (CD105) Contributes to Platinum Resistance and Is a Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer,” November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4549fad5ffada486bf269e6c16dc29b4&authtype=sso&custid=ns315887.